IO BIOTECH, INC. DelveInsight's, "Melanoma Pipeline Insight 2024" report provides comprehensive insights about 150+ companies and 170+ pipeline drugs in Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Melanoma Pipeline Report
*DelveInsight's Melanoma Pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for Melanoma treatment. *The leading Melanoma Companies working in the market include
Request a sample and discover the recent advances in Melanoma treatment drugs @ Melanoma Pipeline Outlook Report
Melanoma Overview
Melanoma is considered as a type of cancer that develops in the pigment-producing melanocyte cells. Anyway, tumors will grow in melanocytes of the skin in almost 90% of cases; it can also occur in melanocytes of the eye, internal organs, and mucosal membranes lining the gastrointestinal, respiratory and urogenital tracts. Melanoma is the third most common cutaneous malignancy after basal cell carcinoma and squamous cell carcinoma. Melanoma is the fifth most common malignancy in males and sixth most common malignancy in females. It is considered one of the most challenging diseases to treat with pharmacotherapy; melanoma drug development lagged than many other cancers, going on in decades with limited progress.
Melanoma Emerging Drugs Profile
IO102 IO103 :
IO102-IO103 is an investigational immune-modulating therapeutic cancer vaccine designed to target the immunosuppressive mechanisms mediated by the proteins indoleamine 2,3-dioxygenase (IDO) and programmed death-ligand 1 (PD-L1). IDO and/or PD-L1 are overexpressed by many types of solid tumors and immune-suppressive cells (Tregs and TAMs) in the TME. The company is developing this vaccine based on its T-win® vaccine platform. Currently it is in Phase III stage of clinical trial evaluation to treat Melanoma.
mRNA 4157:
mRNA-4157/V940 is a novel investigational messenger ribonucleic acid (mRNA)-based personalized cancer vaccine consisting of a single synthetic mRNA coding for up to 34 neoantigens that is designed to stimulate an immune response by generating specific T cell responses based on the unique mutational signature of a patient's tumor. The drug is been developed jointly by
MK-4830:
MK-4830 is an investigational monoclonal antibody that inhibits the binding of Immunoglobulin-like transcript 4 (ILT-4) to its ligands. The drug candidate is being developed in combination with KEYTRUDA. MK-4830 is being developed under an agreement with
BNT111:
BNT111 is an intravenous therapeutic cancer immunotherapy candidate encoding a fixed set of four cancer-specific antigens optimized for immunogenicity and delivered as RNA-lipoplex formulation. The drug induces novel antigen-specific anti-tumor immune responses and enhances pre-existing immune responses against the encoded melanoma-associated antigens. The drug is in Phase II stage of clinical trials.
TILT 123:
TILT-123 is a human 5/3 chimeric adenovirus that has been engineered to encode human Tumor Necrosis Factor alpha (hTNFa) and human Interleukin 2 (hIL-2) cytokines. It is optimized to generate an anti-cancer immune response by boosting the activity of T-cells and also stimulating other arms of the innate and adaptive immune system. TILT-123 can be administered by intravenous, intratumoral, intraperitoneal and intrapleural injection. The drug is in Phase I stage of clinical trials.
Find out more about Melanoma treatment drugs @ Drugs for Melanoma Treatment
Melanoma Therapeutics Assessment
There are approx. 150+ key Melanoma companies which are developing the therapies for Colorectal Cancer. The Melanoma companies which have their Melanoma drug candidates in the most advanced stage, i.e. phase III include,
DelveInsight's Melanoma pipeline report covers around 170+ products under different phases of clinical development like
*Late stage products (Phase III) *Mid-stage products (Phase II) *Early-stage product (Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates
Learn more about the emerging Melanoma pipeline therapies @ Melanoma Clinical Trials
Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
*Oral *Parenteral *intravenous *Subcutaneous *Topical.
Melanoma Products have been categorized under various Molecule types such as
*Monoclonal Antibody *Peptides *Polymer *Small molecule *Gene therapy
Melanoma Companies
Dive deep into rich insights for new drugs for Melanoma Treatment, visit @ Melanoma Drugs
Scope of the Melanoma Pipeline Report
*Coverage- Global *Melanoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination *Melanoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III *Melanoma Companies-
For further information on the Melanoma Pipeline Therapeutics, reach out @ Melanoma Treatment Drugs
Table of Content
*Introduction *Executive Summary *Melanoma: Overview *Pipeline Therapeutics *Therapeutic Assessment *Late Stage Products (Phase III) *Comparative Analysis *IO102 IO103 :
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source
